A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2)

PHASE3CompletedINTERVENTIONAL
Enrollment

153

Participants

Timeline

Start Date

May 17, 2016

Primary Completion Date

March 15, 2017

Study Completion Date

June 7, 2017

Conditions
Hepatitis C Virus InfectionHuman Immunodeficiency Virus InfectionChronic Hepatitis CCompensated Cirrhosis and Non-cirrhotics
Interventions
DRUG

ABT-493 coformulated with ABT-530

Tablet

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AbbVie

INDUSTRY